Taysha Gene Therapies, Inc. - Common Stock (NQ:TSHA)

4.130 -0.090 (-2.13%)

Delayed Quote Updated: 4:00 PM EDT, Oct 30, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Taysha Gene Therapies, Inc. - Common Stock

< Previous 1 2

...

5 6 7 8 9 10 11 12 Next >

Astellas Pharma Invests $50M To Support Taysha's Gene Therapy Programs ↗

October 25, 2022

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

October 25, 2022

Gainers Taysha Gene Therapies (NASDAQ:TSHA) stock increased by 36.4% to $2.06 during Tuesday's pre-market session. The market value of their outstanding shares is at $84.6 million.

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday ↗

October 25, 2022

We're starting off the day with an overview of the biggest pre-market stock movers on Tuesday and the latest news this morning!

Via InvestorPlace

Why Qualtrics International Shares Are Trading Sharply Higher; Here Are 23 Stocks Moving Premarket ↗

October 25, 2022

Gainers Taysha Gene Therapies, Inc. (NASDAQ: TSHA) rose 43% to $2.16 in pre-market trading. Astellas Pharma Inc. announced plans to invest a total of $50 million to acquire 15% of Taysha Gene...

Via Benzinga

Stocks That Hit 52-Week Lows On Wednesday ↗

October 19, 2022

On Wednesday, 200 companies hit new 52-week lows.

Via Benzinga

Expert Ratings for Taysha Gene Therapies ↗

May 17, 2022

Within the last quarter, Taysha Gene Therapies (NASDAQ:TSHA) has observed the following analyst ratings:

Via Benzinga

What 4 Analyst Ratings Have To Say About Taysha Gene Therapies ↗

August 12, 2022

Taysha Gene Therapies (NASDAQ:TSHA) has observed the following analyst ratings within the last quarter:

Via Benzinga

Stocks That Hit 52-Week Lows On Wednesday ↗

May 25, 2022

On Wednesday, 215 companies set new 52-week lows.

Via Benzinga

Stocks That Hit 52-Week Lows On Monday ↗

May 16, 2022

On Monday, 198 companies reached new 52-week lows.

Via Benzinga

Taysha Gene Therapies: Q1 Earnings Insights ↗

May 16, 2022

Taysha Gene Therapies (NASDAQ:TSHA) reported its Q1 earnings results on Monday, May 16, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Via Benzinga

Earnings Scheduled For May 16, 2022 ↗

May 16, 2022

Companies Reporting Before The Bell • AcelRx Pharmaceuticals (NASDAQ:ACRX) is estimated to report quarterly loss at $0.06 per share on revenue of $550.00 thousand.

Via Benzinga

Stocks That Hit 52-Week Lows On Tuesday ↗

April 26, 2022

During Tuesday, 581 stocks hit new 52-week lows. Interesting Highlights From Today's 52-Week Lows Meta Platforms (NASDAQ:FB) was the biggest company on a market cap basis to set a new 52-week low.

Via Benzinga

Taysha Gene Therapies Lays Off 35% Of staff, Narrows R&D Focus ↗

March 31, 2022

Taysha Gene Therapies Inc (NASDAQ: TSHA) is the latest company to slim down by

Via Benzinga

Why FlexShopper Surged Over 47%; Here Are 104 Biggest Movers From Yesterday ↗

August 12, 2022

Gainers Digital Media Solutions, Inc. (NYSE: DMS) jumped 78.8% to close at $2.11. Digital Media Solutions recently reported worse-than-expected Q2 EPS and sales results.

Via Benzinga

Stocks That Hit 52-Week Lows On Tuesday ↗

May 24, 2022

On Tuesday, 540 companies set new 52-week lows.

Via Benzinga

The Daily Biotech Pulse: FDA's AdComm For Acadia's Pimavanserin, Review Issues For Spero's Tebipenem Application, Cortexyme Layoffs ↗

May 03, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours.

Via Benzinga

Stocks That Hit 52-Week Lows On Friday ↗

April 29, 2022

On Friday, 213 companies hit new 52-week lows.

Via Benzinga

What 6 Analyst Ratings Have To Say About Taysha Gene Therapies ↗

April 01, 2022

Analysts have provided the following ratings for Taysha Gene Therapies (NASDAQ:TSHA) within the last quarter:

Via Benzinga

10 Biggest Price Target Changes For Friday ↗

April 01, 2022

Wells Fargo lowered the price target on General Motors Company (NYSE: GM) from $83 to $72. GM shares rose 0.8% to $44.10 in pre-market trading.

Via Benzinga

Recap: Taysha Gene Therapies Q4 Earnings ↗

March 31, 2022

Taysha Gene Therapies (NASDAQ:TSHA) reported its Q4 earnings results on Thursday, March 31, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Via Benzinga

The Daily Biotech Pulse: Amylyx Announces Negative Adcom Vote, Clovis Jumps On Ovarian Cancer Data, Masimo Warns Of Q1 Shortfall ↗

March 31, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Taysha Gene Therapies Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

March 31, 2022

From Taysha Gene Therapies, Inc.

Via Business Wire

Taysha Gene Therapies's Earnings Outlook ↗

March 30, 2022

Taysha Gene Therapies (NASDAQ:TSHA) is set to give its latest quarterly earnings report on Thursday, 2022-03-31. Here's what investors need to know before the announcement. Analysts estimate that...

Via Benzinga

Earnings Scheduled For March 31, 2022 ↗

March 31, 2022

Companies Reporting Before The Bell • Trevena (NASDAQ:TRVN) is likely to report earnings for its fourth quarter.

Via Benzinga

The Daily Biotech Pulse: Roche's Lung Cancer Combo Therapy Flunks Late-Stage Study, Adagio Spikes On Positive COVID Antibody Data, Amylyx Awaits Adcom Verdict ↗

March 30, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours.

Via Benzinga

Taysha Gene Therapies Announces Initiation of Clinical Development of TSHA-102 in Rett Syndrome

March 29, 2022

From Taysha Gene Therapies, Inc.

Via Business Wire

The Week Ahead In Biotech (March 27-April 2): Lipocine, Akebia, Merck Await FDA Verdicts, Adcom Test For Amylyx, BioNTech Earnings And More ↗

March 27, 2022

Biotech stocks reversed course in the week ending March 25, as an increase in risk appetite prompted traders to move money out of defensives and into risky bets.

Via Benzinga

Taysha Gene Therapies Earnings Conference Call Is Coming Up, Here's What You Need To Know ↗

March 25, 2022

Taysha Gene Therapies (NASDAQ:TSHA) will host a conference call at 08:00 AM ET on March 31, 2022, to discuss Q4 2021 earnings results. How to Attend Taysha Gene Therapies (TSHA)...

Via Benzinga

Taysha Gene Therapies to Release Fourth Quarter and Full-Year 2021 Financial Results and Host Conference Call and Webcast on March 31

March 24, 2022

From Taysha Gene Therapies, Inc.

Via Business Wire

Taysha Gene Therapies to Participate in Upcoming April Investor Healthcare Conferences

March 23, 2022

From Taysha Gene Therapies, Inc.

Via Business Wire

< Previous 1 2

...

5 6 7 8 9 10 11 12 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.